Stocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), LiveHire (ASX:LVH), Forbidden Foods (ASX:FFF) and Estrella Resources (ASX:ESR).
Read More
Immutep Limited
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease.
The company are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response.
Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
Corporate Connect Research Report
DOWNLOAD RESEARCH
DOWNLOAD RESEARCH
Spotlight Videos
Stocks of the Hour: Immutep, LiveHire, Forbidden Foods, Estrella Resources
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), LiveHire (ASX:LVH), Forbidden Foods (ASX:FFF) and Estrella Resources (ASX:ESR).
WATCH VIDEOAll Immutep Limited Content
News
Clinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.
Read More
Immutep receives positive FDA feedback
Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment.
Read More
Stocks of the Hour: Immutep, Middle Island Resources, Inca Minerals
A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Middle Island Resources (ASX:MDI) and Inca Minerals (ASX:ICG).
Read More
Immutep (ASX:BLA) – TACTI-003 positive data in patients with negative PD-L1 expression (cohort B)
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep's latest clinical results.
Read More
